RISE THERAPEUTICS LLC
- ROCKVILLE, MD 20850-3192
- risetherapeutics.com (company website, opens in a new tab)
- Partnership or Limited Liability Partnership
- SAM expiring
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
SAM.gov registration expires in 42 days
RISE THERAPEUTICS LLC’s registration expires on Dec 25, 2026. Renewal can take weeks; confirm it stays active through proposal submission and award.
View on SAM.gov (opens in a new tab)Learn more about SAM registration and the UEI
About RISE THERAPEUTICS LLC
- Headquarters
- ROCKVILLE, MD 20850-3192
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIN36JMJ1DKWH6
- CAGE7U7H1
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 21 awards
- Total awarded
- $31,180,267
- By phase
- SBIR Phase II: 13
- SBIR Phase I: 8
- By agency
- Department of Health and Human Services: 21
- Active projects
- 2 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 2 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2024: 3
- 2023: 5
- 2022: 4
- 2021: 3
- 2020: 2
- 2019: 2
- 2018: 2
Awards (most recent first)
A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $1,377,944
Sep 16, 2024 – Jun 30, 2027
- Active
- Ends Jun 2027
Solicitation PAR23-219 (2023) · Topic 300
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $1,783,762
Jul 22, 2024 – Jun 30, 2026
Solicitation PA22-176 (2022) · Topic NIAID
A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $1,940,192
Jul 1, 2024 – Jun 30, 2027
- Active
- Ends Jun 2027
Solicitation PA22-177 (2022) · Topic NIA
A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $494,488
Sep 4, 2023 – Feb 29, 2024
Solicitation PA22-177 (2022) · Topic NIA
R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $1,995,869
Sep 1, 2023 – Aug 31, 2025
Solicitation PA22-177 (2022) · Topic 200
A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $1,916,612
Aug 1, 2023 – Jul 31, 2025
Solicitation PA21-260 (2021) · Topic 300
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $306,499
Apr 24, 2023 – Mar 31, 2024
Solicitation PA22-176 (2022) · Topic NIAID
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,011,001
Jan 17, 2023 – Dec 31, 2024
Solicitation PA21-259 (2021) · Topic NIAID
A Novel Probiotic Drug Delivery Platform for Oral Administration of Protein-Based Therapies
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $282,514
Jul 15, 2022 – Jul 14, 2023
Solicitation PA21-259 (2021) · Topic 100
A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $360,624
Jul 5, 2022 – Jun 30, 2023
Solicitation PA21-260 (2021) · Topic 300
A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $2,083,016
Jul 1, 2022 – Jun 30, 2024
- Direct to Phase II
Solicitation PA21-259 (2021) · Topic NIDDK
A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $2,049,311
Jul 1, 2022 – Jun 30, 2025
Solicitation PA20-260 (2020) · Topic 102
A Novel Probiotic for the Treatment of Sjogren's Syndrome
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $2,918,422
May 12, 2021 – Apr 30, 2024
Solicitation PAR20-129 (2020) · Topic NIDCR
A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $386,860
Apr 1, 2021 – Mar 31, 2022
Solicitation PA20-260 (2020) · Topic 102
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $2,922,693
Feb 23, 2021 – Jan 31, 2024
- Direct to Phase II
Solicitation PA19-272 (2019) · Topic NIAID
A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $2,845,003
Jul 1, 2020 – Jun 30, 2023
Solicitation PA19-272 (2019) · Topic NIAID
A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $2,301,950
May 20, 2020 – Sep 30, 2023
Solicitation PA21-345 (2019) · Topic 300
A Novel Probiotic for the Treatment of Sjogren's Syndrome
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $1,906,163
Jul 10, 2019 – Jun 30, 2021
Solicitation PA18-574 (2018) · Topic NIDCR
A Novel Probiotic Engineered for Enhanced Immunological Function for Treating Inflammatory Bowel Disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $516,894
Feb 15, 2019 – Jul 31, 2021
Solicitation PA18-574 (2018) · Topic NIAID
A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $480,497
Jul 1, 2018 – Jun 30, 2019
Solicitation PA17-302 (2017) · Topic 300
A novel Probiotic for Preventing and Treating Clostridium Difficile Pathogenesis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $299,953
Feb 6, 2018 – Jan 31, 2020
Solicitation PA17-302 (2017) · Topic NIAID
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 325412Pharmaceutical Preparation ManufacturingPrimary
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with RISE THERAPEUTICS LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.